VXRT Share Price Performance
US$0.49
0.09 (23.75%)
87.6% undervalued intrinsic discount
US$4.00
Fair Value
Price US$0.49
AnalystHighTarget US$4.00
AnalystConsensusTarget US$3.33
AnalystLowTarget US$2.00
Fair ValueUS$4.00
Share Pricen/a
Vaxart, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 32 Fair Values set on narratives written by author
VXRT Community Narratives
AN
Fair Value
·Fair Value US$4 87.6% undervalued intrinsic discount
Oral Vaccine Platform And Dynavax Partnership Will Transform Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$3.33 85.2% undervalued intrinsic discount
Oral Vaccine Platform And Norovirus Opportunity Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$2 75.3% undervalued intrinsic discount
BARDA Reliance And Funding Risks Will Shape Oral Vaccine Prospects Longer Term
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
BARDA Reliance And Funding Risks Will Shape Oral Vaccine Prospects Longer Term
Vaxart is trying to turn vaccines into an easy-to-take pill, but the path forward depends heavily on government-backed COVID studies and a partner’s decision to keep supporting the program. The bigger question is whether its pill approach can truly stand out against established shots while it keeps funding new trials without leaning too hard on new share sales.Read more
AN
US$2
75.3% undervalued intrinsic discount
Fair Value
Revenue
-57.66% p.a.
Profit Margin
18.87%
Future PE
194.25x
Price in 2029
US$2.47
Oral Vaccine Platform And Dynavax Partnership Will Transform Long Term Prospects
Catalysts About Vaxart Vaxart is a clinical stage vaccine company developing oral pill vaccines that aim to induce both systemic and mucosal immunity. What are the underlying business or industry changes driving this perspective?Read more
AN
US$4
87.6% undervalued intrinsic discount
Fair Value
Profit Margin
16.24%
Future PE
66.12x
Price in 2029
US$4.97
Oral Vaccine Platform And Norovirus Opportunity Will Drive Long Term Upside Potential
Catalysts About Vaxart Vaxart develops oral tablet vaccines designed to generate both systemic and mucosal immunity against infectious diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
US$3.33
85.2% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
177.4x
Price in 2028
US$4.13
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
BARDA Reliance And Funding Risks Will Shape Oral Vaccine Prospects Longer Term
Fair Value: US$2 75.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Oral Vaccine Platform And Dynavax Partnership Will Transform Long Term Prospects
Fair Value: US$4 87.6% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Oral Vaccine Platform And Norovirus Opportunity Will Drive Long Term Upside Potential
Fair Value: US$3.33 85.2% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vaxart, Inc. Key Details
About VXRT
- Founded
- n/a
- Employees
- 65
- CEO
- WebsiteView website
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
